Search results
FTC is 'just getting started' as it takes on Amazon, Meta and more, Chair Lina Khan says
ABC News· 6 days agoIn the nearly three years since President Joe Biden appointed Lina Khan as chair of the Federal...
Opinion | Lina Khan’s Failed FTC Experiment
The Wall Street Journal· 4 days agoBad management, poor strategy and disregard for norms have foiled her plan to refashion antitrust law.
Antitrust agencies are relying on consumers to report anticompetitive behavior. That trust might be...
Healthcare Dive via Yahoo Finance· 5 days agoRegulators want consumers to flag business practices harming market health in the healthcare sector,...
FTC Chief Says Tech Advancements Risk Healthcare Price Fixing
MedPage Today· 2 weeks agoAlgorithms make it possible for companies to fix prices without explicitly coordinating with one...
Will The FTC Reinvigorate An Antiquated Law That Raises Prices?
Forbes· 5 days agoAs such, reinvigorated enforcement of the...wish to consider the major downsides of RPA prosecutions...
U.S. Antitrust Case Against Google Is Just the Start
New York Times· 1 week agoAs the Justice Department’s case against Google nears an end, the federal government has more suits in the pipeline trying to rein in Big Tech. The U.S....
Opinion | How the FTC Protects Patients in Healthcare
MedPage Today· 4 days agoIn Part 1 of this exclusive video interview, MedPage Today editor-in-chief Jeremy Faust, MD, and ...
FTC Pioneers Novel Remedies in the Exxon/Pioneer Merger | JD Supra
JD Supra· 3 days ago...authored a joint dissenting statement expressing concern that the FTC is “leveraging its merger enforcement authority to extract a consent from Exxon” without articulating how the transaction violates Section 7 of the Clayton Act.3 FTC Chair Lina Khan and Commissioners Alvaro Bedoya and Rebecca...
US Clears ExxonMobil Deal, Bars Pioneer Ex-chief From Board
International Business Times· 1 week agoUS antitrust authorities cleared ExxonMobil's acquisition of Pioneer Natural Resources under the...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 1 week agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...